

Table S1. Bone biomarkers according to metastatic compartment.

Characteristic	BOM	BESM	<i>p</i> -Value
Baseline assessment			
Uncorrected uNTX, nmol BCE/mmol creatinine			
Median	513	434	
P25–P75	246–1214	209–1040	
Min.–max.	63–18,571	63–28,571	0.044
Corrected uNTX, nmol BCE/mmol creatinine			
Median	48	48	
P25–P75	27–100	25–85	0.277
Min.–max.	4–3 904	4–1 786	
Corrected NTX, <i>n</i> (%)			
High	628 (42.6)	131 (40.1)	
Normal	848 (57.5)	196 (59.9)	0.410
bALP, ng/mL			
Median	31	29	
P25–P75	17–74	17–75	0.899
Min.–max.	4–1 363	0–1941	
bALP, <i>n</i> (%)			
High	1012 (66.9)	221 (66.2)	
Normal	500 (33.1)	113 (33.8)	0.789
3-month assessment			
Uncorrected uNTX, nmol BCE/mmol creatinine			
Median	71	77	
P25–P75	63–162	63–161	0.796
Min.–max.	63–17,984	63–5802	
Corrected uNTX, nmol BCE/mmol creatinine			
Median	9	10	
P25–P75	6–21	6–21	0.428
Min.–max.	2–1754	3–556	
Corrected uNTX, <i>n</i> (%)			
High	113 (9.1)	19 (7.4)	
Normal	1136 (90.9)	237 (92.6)	0.402
Corrected uNTX normalization ¹ , <i>n</i> (%)			
Yes	364 (80.2)	77 (85.6)	
No	90 (19.8)	13 (14.4)	0.234
bALP, ng/mL			
Median	20	20	
P25–P75	11–67	11–61	0.916
Min.–max.	3–1461	4–640	
bALP, <i>n</i> (%)			
High	622 (50.1)	125 (49.4)	
Normal	620 (49.9)	128 (50.6)	0.845
bALP normalization ¹ , <i>n</i> (%)			
Yes	236 (29.0)	56 (32.9)	
No	577 (71.0)	114 (67.1)	0.310

ALP, alkaline phosphatase; BOM, bone-only metastases; BESMD, bone and extra-skeletal metastases; uNTX, urinary N-terminal telopeptide; P25, Percentile 25; P75, Percentile 75.¹If elevated at baseline. Cut-off for normal uNTX <64 nmol BCE/mmol creatinine; cut-off for normal bALP <22 ng/mL, as per R. Coleman 2011 CROH [13].